← Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) Financials

Q2 FY2026, built from SEC filings. Accession numbers are cited throughout so every figure can be checked against sec.gov. The same data is published as JSON at financials.json for agents that prefer to fetch it directly.

Download financials.json

About this file

Ticker	JNJ
CIK	0000200406
Company	Johnson & Johnson
Business type	pharmaceutical and medical technology (standard industrial/consumer template, extended with segment revenue, segment pre-tax income and R&D expense)
Schema rationale	Johnson & Johnson is a two-segment healthcare products company (Innovative Medicine and MedTech). The standard revenue / cost of products sold / gross profit / net income / EPS / balance-sheet / cash-flow template fits it directly. Because research and development and the two-segment split are central to how the business earns money, segment sales, segment pre-tax income and R&D expense are reported alongside the standard lines. Johnson & Johnson does not present an 'operating income' subtotal on the face of its statement of earnings, so an operating income figure is derived here (gross profit less selling, marketing and administrative expenses, research and development expense, in-process research and development impairments and restructuring) and is labeled as derived wherever it appears.
Reporting currency	USD
Converted to USD	no
Units	actual dollars (not millions); per-share figures are in actual dollars per share; share counts are actual shares
Fiscal calendar note	Johnson & Johnson uses a 52/53-week fiscal year ending on the Sunday nearest to December 31. Fiscal 2025 ended December 28, 2025; fiscal 2024 ended December 29, 2024; fiscal 2023 ended December 31, 2023. The fiscal 2026 second quarter ended June 28, 2026.

Annual

	FY2025	FY2024	FY2023
Fiscal year	2025	2024	2023
Period end	2025-12-28	2024-12-29	2023-12-31
Period label	Fiscal year 2025 (52 weeks ended December 28, 2025)	Fiscal year 2024 (52 weeks ended December 29, 2024)	Fiscal year 2023 (53 weeks ended December 31, 2023)
Source accession	0000200406-26-000016	0000200406-26-000016	0000200406-26-000016
Source form	10-K filed 2026-02-11	10-K filed 2026-02-11 (comparative columns)	10-K filed 2026-02-11 (comparative columns; balance sheet not presented for this year)
Income statement
Revenue	94,193,000,000	88,821,000,000	85,159,000,000
Cost of products sold	30,256,000,000	27,471,000,000	26,553,000,000
Gross profit	63,937,000,000	61,350,000,000	58,606,000,000
Gross margin %	67.9%	69.1%	68.8%
Selling marketing and administrative expenses	23,676,000,000	22,869,000,000	21,512,000,000
Research and development expense	14,665,000,000	17,232,000,000	15,085,000,000
In process rd impairments	81,000,000	211,000,000	313,000,000
Restructuring	228,000,000	234,000,000	489,000,000
Operating income derived	25,287,000,000	20,804,000,000	21,207,000,000
Interest income	1,056,000,000	1,332,000,000	1,261,000,000
Interest expense net of capitalized	971,000,000	755,000,000	772,000,000
Other income expense net	-7,209,000,000	4,694,000,000	6,634,000,000
Pretax income	32,581,000,000	16,687,000,000	15,062,000,000
Provision for taxes on income	5,777,000,000	2,621,000,000	1,736,000,000
Effective tax rate %	17.7%	15.7%	11.5%
Net earnings continuing operations	26,804,000,000	14,066,000,000	13,326,000,000
Net earnings discontinued operations	0	0	21,827,000,000
Net income	26,804,000,000	14,066,000,000	35,153,000,000
EPS basic	11.13	5.84	13.88
EPS diluted	11.03	5.79	13.72
Weighted average shares basic	2,407,400,000	2,407,300,000	2,533,500,000
Weighted average shares diluted	2,429,400,000	2,429,400,000	2,560,400,000
Dividends paid per share	5.14	4.91	4.7
EPS basic continuing operations			5.26
EPS diluted continuing operations			5.2
Segments
Innovative medicine
Sales to customers	60,401,000,000	56,964,000,000	54,759,000,000
Cost of products sold	15,646,000,000	14,036,000,000	13,715,000,000
Selling marketing and administrative	11,375,000,000	10,906,000,000	9,842,000,000
Research and development expense	11,827,000,000	13,529,000,000	11,963,000,000
Other segment items	-713,000,000	-426,000,000	993,000,000
Segment income before tax	22,266,000,000	18,919,000,000	18,246,000,000
Identifiable assets	78,057,000,000	57,070,000,000
Additions to ppe	2,076,000,000	1,710,000,000	1,653,000,000
Depreciation and amortization	3,772,000,000	3,760,000,000	3,847,000,000
Medtech
Sales to customers	33,792,000,000	31,857,000,000	30,400,000,000
Cost of products sold	14,549,000,000	13,345,000,000	12,722,000,000
Selling marketing and administrative	11,354,000,000	10,812,000,000	10,476,000,000
Research and development expense	2,838,000,000	3,703,000,000	3,122,000,000
Other segment items	938,000,000	257,000,000	-589,000,000
Segment income before tax	4,113,000,000	3,740,000,000	4,669,000,000
Identifiable assets	86,482,000,000	84,322,000,000
Additions to ppe	2,501,000,000	2,443,000,000	2,372,000,000
Depreciation and amortization	3,490,000,000	3,237,000,000	2,943,000,000
Total segment income before tax	26,379,000,000	22,659,000,000	22,915,000,000
Income expense not allocated to segments	-6,202,000,000	5,972,000,000	7,853,000,000
Geography
United states sales	53,752,000,000	50,302,000,000	46,444,000,000
International sales	40,441,000,000	38,519,000,000	38,715,000,000
Europe sales	21,535,000,000	20,212,000,000	20,410,000,000
Western hemisphere excluding US sales	4,875,000,000	4,714,000,000	4,549,000,000
Asia pacific africa sales	14,031,000,000	13,593,000,000	13,756,000,000
Balance sheet
Cash and cash equivalents	19,709,000,000	24,105,000,000
Marketable securities	393,000,000	417,000,000
Cash and marketable securities	20,102,000,000	24,522,000,000
Accounts receivable trade net	17,178,000,000	14,842,000,000
Inventories	14,191,000,000	12,444,000,000
Prepaid expenses and other receivables	4,153,000,000	4,085,000,000
Total current assets	55,624,000,000	55,893,000,000
Property plant and equipment net	23,169,000,000	20,518,000,000
Intangible assets net	50,403,000,000	37,618,000,000
Goodwill	48,772,000,000	44,200,000,000
Deferred taxes on income asset	6,874,000,000	10,461,000,000
Other assets	14,368,000,000	11,414,000,000
Total assets	199,210,000,000	180,104,000,000
Loans and notes payable current	8,495,000,000	5,983,000,000
Accounts payable	11,991,000,000	10,311,000,000
Accrued liabilities	8,594,000,000	8,549,000,000
Accrued rebates returns and promotions	19,124,000,000	17,580,000,000
Accrued compensation and employee related obligations	4,534,000,000	4,126,000,000
Accrued taxes on income	1,388,000,000	3,772,000,000
Total current liabilities	54,126,000,000	50,321,000,000
Long term debt	39,438,000,000	30,651,000,000
Deferred taxes on income liability	6,791,000,000	2,448,000,000
Employee related obligations	6,957,000,000	7,255,000,000
Long term taxes payable	486,000,000	390,000,000
Other liabilities	9,868,000,000	17,549,000,000
Total liabilities	117,666,000,000	108,614,000,000
Total debt derived	47,933,000,000	36,634,000,000
Net debt derived	27,831,000,000	12,112,000,000
Total shareholders equity	81,544,000,000	71,490,000,000
Common shares issued	3,119,843,000	3,119,843,000
Treasury shares	711,904,000	712,921,000
Shares outstanding derived	2,407,939,000	2,406,922,000
Book value per share derived	33.86	29.7
Cash flow
Net earnings	26,804,000,000	14,066,000,000	35,153,000,000
Depreciation and amortization	7,503,000,000	7,339,000,000	7,486,000,000
Stock based compensation	1,354,000,000	1,176,000,000	1,162,000,000
Deferred tax provision	1,538,000,000	-2,183,000,000	-4,194,000,000
Operating cash flow	24,530,000,000	24,266,000,000	22,791,000,000
Capital expenditures	4,832,000,000	4,424,000,000	4,543,000,000
Free cash flow derived	19,698,000,000	19,842,000,000	18,248,000,000
Acquisitions net of cash acquired	17,541,000,000	15,146,000,000	0
Acquired ipr and d and milestones	385,000,000	1,783,000,000	470,000,000
Investing cash flow	-23,588,000,000	-18,599,000,000	878,000,000
Dividends paid	12,381,000,000	11,823,000,000	11,770,000,000
Share repurchases	5,953,000,000	2,432,000,000	5,054,000,000
Financing cash flow	-5,539,000,000	-3,132,000,000	-15,825,000,000
Cash paid for interest	1,977,000,000	1,990,000,000	1,836,000,000
Cash paid for income taxes	6,539,000,000	6,714,000,000	8,574,000,000
Gain on kenvue separation			-20,984,000,000
Note			The 10-K states that amounts presented for 2023 in the statement of cash flows have not been recast to exclude discontinued operations, so the fiscal 2023 cash flow figures include the Consumer Health business separated as Kenvue.
Balance sheet note			The FY2025 10-K balance sheet presents only December 28, 2025 and December 29, 2024, so no fiscal 2023 balance sheet is reported here.

Quarterly

	2026-06-28	2025-06-29	2026-06-28	2025-06-29	2026-03-29
Period label	Fiscal second quarter 2026 (13 weeks ended June 28, 2026)	Fiscal second quarter 2025 (13 weeks ended June 29, 2025), prior-year comparative	Fiscal six months 2026 (26 weeks ended June 28, 2026)	Fiscal six months 2025 (26 weeks ended June 29, 2025), prior-year comparative	Fiscal first quarter 2026 (13 weeks ended March 29, 2026), derived
Period type	quarter	quarter	year_to_date	year_to_date	quarter_derived
Period start	2026-03-30	2025-03-31	2025-12-29	2024-12-30	2025-12-29
Period end	2026-06-28	2025-06-29	2026-06-28	2025-06-29	2026-03-29
Source accession	0000200406-26-000153	0000200406-26-000153	0000200406-26-000153	0000200406-26-000153	0000200406-26-000153
Source form	10-Q filed 2026-07-23	10-Q filed 2026-07-23 (comparative columns)	10-Q filed 2026-07-23	10-Q filed 2026-07-23 (comparative columns)	Derived by subtracting the fiscal second quarter 2026 columns from the fiscal six months 2026 columns of the 10-Q filed 2026-07-23
Income statement
Revenue	25,310,000,000	23,743,000,000	49,372,000,000	45,636,000,000	24,062,000,000
Cost of products sold	8,051,000,000	7,628,000,000	16,157,000,000	14,985,000,000	8,106,000,000
Gross profit	17,259,000,000	16,115,000,000	33,215,000,000	30,651,000,000	15,956,000,000
Gross margin %	68.2%	67.9%	67.3%	67.2%
Selling marketing and administrative expenses	6,432,000,000	5,889,000,000	12,466,000,000	11,001,000,000
Research and development expense	3,653,000,000	3,516,000,000	7,180,000,000	6,741,000,000	3,527,000,000
Restructuring	34,000,000	64,000,000	66,000,000	81,000,000
Operating income derived	7,140,000,000	6,646,000,000	13,467,000,000	12,828,000,000
Interest income	219,000,000	260,000,000	448,000,000	592,000,000
Interest expense net of capitalized	281,000,000	308,000,000	553,000,000	512,000,000
Other income expense net	331,000,000	107,000,000	625,000,000	-7,214,000,000
Pretax income	6,747,000,000	6,491,000,000	12,737,000,000	20,122,000,000	5,990,000,000
Provision for taxes on income	1,213,000,000	954,000,000	1,968,000,000	3,586,000,000
Effective tax rate %	18.0%	14.7%	15.5%	17.8%
Net income	5,534,000,000	5,537,000,000	10,769,000,000	16,536,000,000	5,235,000,000
Net margin %	21.9%	23.3%	21.8%	36.2%
EPS basic	2.3	2.3	4.47	6.87
EPS diluted	2.27	2.29	4.41	6.82
Weighted average shares basic	2,407,400,000	2,406,300,000	2,408,100,000	2,406,700,000
Weighted average shares diluted	2,440,100,000	2,419,100,000	2,443,900,000	2,423,300,000
Dividends paid per share	1.34	1.3	2.64	2.54
In process rd impairments			36,000,000	0
Segments
Innovative medicine
Sales to customers	16,384,000,000	15,202,000,000	31,810,000,000	29,075,000,000
Cost of products sold	4,296,000,000	3,978,000,000	8,686,000,000	7,998,000,000
Selling marketing and administrative	3,130,000,000	2,789,000,000	6,048,000,000	5,050,000,000
Research and development expense	2,875,000,000	2,869,000,000	5,688,000,000	5,417,000,000
Other segment items	-166,000,000	14,000,000	-178,000,000	-152,000,000
Segment income before tax	6,249,000,000	5,552,000,000	11,566,000,000	10,762,000,000
Medtech
Sales to customers	8,926,000,000	8,541,000,000	17,562,000,000	16,561,000,000
Cost of products sold	3,737,000,000	3,638,000,000	7,438,000,000	6,964,000,000
Selling marketing and administrative	3,069,000,000	2,862,000,000	5,975,000,000	5,518,000,000
Research and development expense	778,000,000	647,000,000	1,492,000,000	1,324,000,000
Other segment items	165,000,000	190,000,000	241,000,000	130,000,000
Segment income before tax	1,177,000,000	1,204,000,000	2,416,000,000	2,625,000,000
Total segment income before tax	7,426,000,000	6,756,000,000	13,982,000,000	13,387,000,000
Income expense not allocated to segments	679,000,000	265,000,000	1,245,000,000	-6,735,000,000
Balance sheet
As of	2026-06-28
Cash and cash equivalents	20,422,000,000
Marketable securities	336,000,000
Cash and marketable securities	20,758,000,000
Accounts receivable trade net	19,046,000,000
Inventories	15,144,000,000
Prepaid expenses and other	4,826,000,000
Total current assets	59,774,000,000
Property plant and equipment gross	55,518,000,000
Accumulated depreciation	31,936,000,000
Property plant and equipment net	23,582,000,000
Intangible assets net	48,229,000,000
Goodwill	48,479,000,000
Deferred taxes on income asset	6,728,000,000
Other assets	14,269,000,000
Total assets	201,061,000,000
Loans and notes payable current	11,692,000,000
Accounts payable	9,223,000,000
Accrued liabilities	9,464,000,000
Accrued rebates returns and promotions	19,990,000,000
Accrued compensation and employee related obligations	3,475,000,000
Accrued taxes on income	1,051,000,000
Total current liabilities	54,895,000,000
Long term debt	37,344,000,000
Deferred taxes on income liability	6,608,000,000
Employee related obligations	6,657,000,000
Long term taxes payable	485,000,000
Other liabilities	10,101,000,000
Total liabilities	116,090,000,000
Total debt derived	49,036,000,000
Net debt derived	28,278,000,000
Total shareholders equity	84,971,000,000
Common shares issued	3,119,843,000
Treasury shares	711,615,000
Shares outstanding derived	2,408,228,000
Shares outstanding cover page	2,409,898,597
Shares outstanding cover page date	2026-07-17
Book value per share derived	35.28
Cash flow
Net earnings			10,769,000,000	16,536,000,000
Depreciation and amortization			3,963,000,000	3,715,000,000
Stock based compensation			758,000,000	698,000,000
Deferred tax provision			-320,000,000	2,997,000,000
Operating cash flow			11,130,000,000	8,052,000,000
Capital expenditures			2,370,000,000	1,838,000,000
Free cash flow derived			8,760,000,000	6,214,000,000
Acquisitions net of cash acquired			263,000,000	14,458,000,000
Investing cash flow			-2,150,000,000	-18,561,000,000
Dividends paid			6,358,000,000	6,118,000,000
Share repurchases			4,249,000,000	2,127,000,000
Financing cash flow			-8,247,000,000	4,757,000,000
Cash and cash equivalents end of period			20,422,000,000	18,577,000,000
Note					These first-quarter figures are arithmetic differences between the six-month and second-quarter columns of the FY2026 second-quarter 10-Q, not figures presented directly on the face of that filing.

Trailing twelve months

	Value
Period label	Trailing twelve months ended June 28, 2026
Method	Fiscal year 2025 (accession 0000200406-26-000016) plus fiscal six months 2026 less fiscal six months 2025 (both from accession 0000200406-26-000153)
Revenue	97,929,000,000
Net income	21,037,000,000
Research and development expense	15,104,000,000
Operating cash flow	27,608,000,000
Capital expenditures	5,364,000,000
Free cash flow	22,244,000,000
Dividends paid	12,621,000,000
Share repurchases	8,075,000,000
EPS diluted approx	8.62
EPS diluted note	Trailing-twelve-month diluted EPS computed as fiscal 2025 diluted EPS of $11.03 plus fiscal six months 2026 diluted EPS of $4.41 less fiscal six months 2025 diluted EPS of $6.82. Because the weighted average diluted share count differs across those periods, this is an approximation rather than a figure presented in any filing.

Units notes seen

	Value
FY2025 10-K consolidated statements of earnings	(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)
FY2025 10-K consolidated balance sheets	At December 28, 2025 and December 29, 2024, (Dollars in Millions Except Share and Per Share Amounts) (Note 1)
FY2025 10-K consolidated statements of comprehensive income	(Dollars in Millions) (Note 1)
FY2025 10-K consolidated statements of cash flows	(Dollars in Millions) (Note 1)
FY2025 10-K segment tables (income before tax by segment, identifiable assets, additions to PP&E, sales by geography)	(Dollars in Millions)
FY2026 Q2 10-Q consolidated balance sheets	(Unaudited; Dollars in Millions Except Share and Per Share Data)
FY2026 Q2 10-Q consolidated statements of earnings (fiscal second quarter and fiscal six months)	(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
FY2026 Q2 10-Q consolidated statements of cash flows	(Unaudited; Dollars in Millions)
FY2026 Q2 10-Q segment income before tax table	(Dollars in Millions)
Note on shares	Balance-sheet share counts (shares issued and treasury shares) are stated in the filings as full share counts, not in millions, even though the dollar columns of the same tables are in millions. Weighted average share counts on the statements of earnings ARE in millions. Both have been converted to actual shares here.

Adjustments

	Value
Splits applied	none
Splits note	No stock splits apply to the periods reported here, so no per-share figure required split adjustment.
ADR ratio	n/a
FX	None. Johnson & Johnson reports in U.S. dollars, so no currency conversion was applied.

Notes

All figures are stated in actual U.S. dollars. The filings present dollar amounts in millions and weighted average share counts in millions; those have been multiplied out here. Balance-sheet share counts (shares issued and treasury shares) are already stated as full share counts in the filings and were carried across unchanged.
Annual coverage reflects what the FY2025 10-K (accession 0000200406-26-000016) actually presents: three years on the statements of earnings, cash flows and segment tables (fiscal 2025, 2024 and 2023), but only two years on the balance sheet (December 28, 2025 and December 29, 2024). No fiscal 2023 balance sheet is reported for that reason.
Johnson & Johnson does not present an operating income subtotal on the face of its consolidated statements of earnings. The 'operating_income_derived' figures here are computed as gross profit less selling, marketing and administrative expenses, research and development expense, in-process research and development impairments and restructuring. Each derived figure reconciles exactly to the reported pre-tax earnings once interest income, interest expense and other (income) expense, net are added back.
Fiscal 2023 net earnings of $35.153 billion include $21.827 billion of net earnings from discontinued operations, essentially the separation of the Consumer Health business as Kenvue, including a $20.984 billion gain on that separation. Continuing-operations net earnings for fiscal 2023 were $13.326 billion and continuing-operations diluted earnings per share were $5.20. Comparisons of fiscal 2023 total net income to later years are not like-for-like. The 10-K also states that fiscal 2023 cash flow statement amounts have not been recast to exclude discontinued operations.
Fiscal 2025 pre-tax earnings and net earnings are flattered by $7.209 billion of net other income, the large majority of which arose in the first six months of fiscal 2025 (the 10-Q shows $7.214 billion of net other income in the fiscal six months ended June 29, 2025). This is why fiscal six months 2025 net earnings of $16.536 billion exceed fiscal six months 2026 net earnings of $10.769 billion despite higher 2026 sales. Fiscal 2024 pre-tax earnings were correspondingly depressed by $4.694 billion of net other expense and by elevated research and development expense of $17.232 billion, which included large acquired in-process research and development charges.
Research and development expense on the face of the statement of earnings ($14.665 billion in fiscal 2025) is reported by Johnson & Johnson under a tag that excludes acquired in-process research and development costs. In the SEC's XBRL company facts, the plain 'ResearchAndDevelopmentExpense' concept is populated instead with the much smaller charge for acquired in-process research and development ($109 million in fiscal 2025, $1.841 billion in fiscal 2024, $483 million in fiscal 2023). The income statement line as printed in the filing is what is reported here.
Total debt is not a line item in the filings; it is derived here as loans and notes payable plus long-term debt. Net debt is derived as total debt less cash and cash equivalents and marketable securities. Book value per share is derived as total shareholders' equity divided by shares issued less treasury shares.
Cash dividends paid per share come from the consolidated statements of equity and management's discussion: $5.14 in fiscal 2025, $4.91 in fiscal 2024 and $4.70 in fiscal 2023. The fiscal 2025 10-K notes the dividend was increased for the 63rd consecutive year. The FY2026 second-quarter 10-Q shows $1.34 per share paid in the second quarter of 2026 and $2.64 for the six months, and discloses a further $1.34 per share quarterly dividend declared on July 15, 2026, payable September 8, 2026.
A Form 8-K dated July 15, 2026 (accession 0000200406-26-000146) carried the fiscal second quarter 2026 earnings release. The 10-Q filed July 23, 2026 (accession 0000200406-26-000153) covers the same period and is the authoritative source used here; no figure in this file comes from the press release.
The FY2026 second-quarter 10-Q discloses that in October 2025 the Company announced its intention to separate its Orthopaedics business, targeting completion within 18 to 24 months of that announcement. That business is still consolidated in every figure reported here.
Segment 'other segment items' as reported by the Company can be negative, which reduces segment expense and raises segment income before tax. Segment income before tax for the two segments does not sum to consolidated pre-tax earnings; the difference is the income and expense the Company does not allocate to segments, reported separately here.

Uncertainties

Operating income is a derived figure, not a subtotal the Company reports. A reader who prefers to exclude restructuring, in-process research and development impairments, or intangible amortization from operating income would arrive at a different number. The components are all reported here so the derivation can be recomputed.
Trailing-twelve-month diluted earnings per share of about $8.62 is an approximation built from three periods with different weighted average diluted share counts. Trailing-twelve-month revenue, net income and cash flow figures are exact period arithmetic and carry no such caveat.
The fiscal first quarter 2026 figures are derived by subtracting the second-quarter column from the six-month column of the FY2026 second-quarter 10-Q. They are arithmetically sound for the lines shown but were not presented as a first-quarter column in that filing; only revenue, cost of products sold, gross profit, research and development expense, pre-tax income and net income are reported for that period here.
Balance-sheet 'shares outstanding' is derived as shares issued less treasury shares at the balance sheet date (2,408,228,000 at June 28, 2026). The cover page of the same 10-Q reports 2,409,898,597 shares outstanding as of July 17, 2026, a later date; both are shown so the difference is visible.
Fiscal 2023 identifiable assets by segment are not reported here because the segment identifiable-assets table in the FY2025 10-K presents only fiscal 2025 and fiscal 2024.
Effective tax rates shown are computed as provision for taxes on income divided by earnings before provision for taxes on income, and are not the rates the Company discusses in its tax note, which reconcile to the U.S. statutory rate through a number of items.

Company details

	Value
Name	Johnson & Johnson
Ticker	JNJ
CIK	0000200406
Exchange	NYSE
State	New Jersey
Incorporation	New Jersey
SIC	2834
Office	Life Sciences
Industry	Pharmaceutical Preparations

Next filing

	Value
Predicted date	2026-08-06
Predicted type	10-Q

Fiscal period

	FY2026
Fiscal year	2026
Fiscal period	Q2
Tag	FY26Q2
Period end	2026-06-28
Form	10-Q
Accession	0000200406-26-000153
Fiscal year end	0103
Source	facts

Built from Johnson & Johnson's SEC filings by Ticker Scout. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer. Also for this company: company index, financials.json, index.json.